Skip to main content
. 2022 Jun 6;27(8):646–654. doi: 10.1093/oncolo/oyac089

Figure 2.

Figure 2.

(A) Kaplan-Meier analysis of progression-free survival comparing CDK4/6i combinations with fulvestrant vs. letrozole. P = .012 by log-rank. (B) Kaplan-Meier analysis of progression-free survival comparing CDK4/6i combinations with fulvestrant vs. AI. P = .0052 by log-rank. (C) Comparison of the progression-free survival from the real-world setting vs. the indicated randomized trials.